Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607

Watchlist Manager
Shanghai Pharmaceuticals Holding Co Ltd Logo
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Watchlist
Price: 21.23 CNY -0.66%
Market Cap: 60.5B CNY
Have any thoughts about
Shanghai Pharmaceuticals Holding Co Ltd?
Write Note

Gross Margin
Shanghai Pharmaceuticals Holding Co Ltd

10.9%
Current
12%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
10.9%
=
Gross Profit
29.8B
/
Revenue
272.4B

Gross Margin Across Competitors

Country CN
Market Cap 60.9B CNY
Gross Margin
11%
Country US
Market Cap 77.7B USD
Gross Margin
4%
Country US
Market Cap 48.9B USD
Gross Margin
3%
Country US
Market Cap 48.4B USD
Gross Margin
3%
Country US
Market Cap 30.1B USD
Gross Margin
3%
Country US
Market Cap 9.3B USD
Gross Margin
32%
Country CN
Market Cap 65B CNY
Gross Margin
32%
Country KR
Market Cap 12.2T KRW
Gross Margin
30%
Country CN
Market Cap 65.4B HKD
Gross Margin
8%
Country IT
Market Cap 5.5B EUR
Gross Margin
24%
Country DE
Market Cap 5B EUR
Gross Margin
10%
No Stocks Found

Shanghai Pharmaceuticals Holding Co Ltd
Glance View

Market Cap
60.5B CNY
Industry
Health Care

Shanghai Pharmaceuticals Holding Co Ltd, a key player in China's healthcare sector, emerged from its roots in the early 1990s to become one of the largest pharmaceutical companies in the country. It operates in two main segments: pharmaceutical manufacturing and distribution. With a strong portfolio of generic and branded medications, the company leverages its extensive distribution network to reach hospitals and pharmacies across China. Shanghai Pharmaceuticals focuses on innovative drug development and has made significant strides in research, particularly in oncology and high-demand therapeutic areas, positioning itself well for growth in a rapidly evolving market. For investors, Shanghai Pharmaceuticals represents a compelling opportunity, not only due to its robust domestic market but also its potential for international expansion. The company's commitment to R&D, alongside strategic partnerships with global pharmaceutical firms, underscores its forward-thinking approach. Additionally, as China's healthcare reforms push for improved access to medicines, Shanghai Pharmaceuticals stands to benefit from increased demand. With a seasoned management team and a solid track record of consistent revenue growth, investors looking for exposure in the burgeoning Asian pharmaceutical landscape may find Shanghai Pharmaceuticals an attractive addition to their portfolios.

Intrinsic Value
47 CNY
Undervaluation 55%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
10.9%
=
Gross Profit
29.8B
/
Revenue
272.4B
What is the Gross Margin of Shanghai Pharmaceuticals Holding Co Ltd?

Based on Shanghai Pharmaceuticals Holding Co Ltd's most recent financial statements, the company has Gross Margin of 10.9%.